Cardiovascular Drugs Practice Questions

Q: All of the following are centrally acting antihypertensive drugs except:

Trimethoprim. ***Trimethoprim*** - **Trimethoprim** is an **antibiotic** and is not used as an antihypertensive drug. - It works by inhibiting **dihydrofolate reductase**, an enzyme involved in bacterial folate synthesis. *Methyldopa* - **Methyldopa** is a **centrally acting alpha-2 adrenergic agonist** that reduces sympathetic outflow from the central nervous system. - It decreases peripheral vascular resistance and heart rate, leading to a reduction in blood pressure. *Clonidine* - **Clonidine** is a **centrally acting alpha-2 adrenergic agonist** that stimulates alpha-2 receptors in the brainstem. - This stimulation reduces sympathetic outflow, leading to vasodilation and decreased heart rate. *Guanabenz* - **Guanabenz** is also a **centrally acting alpha-2 adrenergic agonist**. - It acts similarly to clonidine by stimulating central alpha-2 receptors to decrease sympathetic tone and lower blood pressure.

Q: Most common digoxin-induced arrhythmia is

Ventricular Premature Beats. ***Ventricular Premature Beats (VPBs)*** - **Most common** digoxin-induced arrhythmia overall, occurring in up to 50-90% of digoxin toxicity cases. - Digoxin increases intracellular calcium through Na+/K+-ATPase inhibition, leading to **increased automaticity** and **delayed afterdepolarizations** that trigger ventricular ectopy. - **Hypokalemia** (common with concurrent diuretic use) significantly increases the risk by enhancing digoxin binding to Na+/K+-ATPase and further elevating intracellular calcium. - VPBs can manifest in various patterns including isolated beats, couplets, or organized patterns like ventricular bigeminy. *Ventricular bigeminy* - While ventricular bigeminy (every other beat is a VPB) is highly **characteristic** and specific for digoxin toxicity, it is a specific *pattern* of VPBs rather than the most common arrhythmia overall. - Represents severe ventricular irritability and indicates significant digoxin effect, but occurs less frequently than isolated VPBs. - When present, it strongly suggests digoxin toxicity and warrants immediate attention. *Ventricular Fibrillation* - A rare but **life-threatening** complication of severe digoxin toxicity. - Usually preceded by other ventricular arrhythmias (VPBs, ventricular tachycardia) and represents advanced toxicity. - Not common enough to be considered the "most common" digoxin-induced arrhythmia. *Atrial Flutter* - Digoxin can cause various atrial arrhythmias, but atrial flutter is relatively uncommon. - The most characteristic **atrial** arrhythmia in digoxin toxicity is **paroxysmal atrial tachycardia (PAT) with AV block**, not atrial flutter. - Digoxin's primary atrial effect is to slow AV nodal conduction, which may actually help control atrial flutter rather than cause it.

Q: Effects of beta blockers on the heart are all of the following except:

Decreases duration of systole. ***Decreases duration of systole*** - Beta-blockers primarily prolong the **duration of systole** by extending the **ejection time** and slowing ventricular relaxation. - They also increase the **diastolic filling time** by reducing heart rate, impacting overall cardiac cycle duration. *Decrease in heart rate* - Beta-blockers block **beta-1 adrenergic receptors** in the heart, leading to a decrease in **sympathetic stimulation** and thus a reduced heart rate. - This effect is beneficial in conditions like **tachycardia** and **angina**, as it reduces myocardial oxygen demand. *May decrease cardiac output initially.* - By reducing heart rate and contractility, beta-blockers can initially decrease **cardiac output**, especially in patients with pre-existing **ventricular dysfunction**. - This effect is often transient, as chronic use can lead to beneficial remodeling and improved efficiency in some conditions. *May precipitate heart failure in acute settings.* - In patients with acutely decompensated heart failure or severe left ventricular dysfunction, beta-blockers can acutely worsen cardiac function due to their **negative inotropic effects**. - Therefore, beta-blockers are typically initiated cautiously at low doses in stable heart failure patients and are contraindicated in acute decompensation.

Q: HMG-CoA reductase is inhibited by:

Lovastatin. ***Lovastatin*** - **Lovastatin** is part of the statin class of drugs, which are potent competitive inhibitors of **HMG-CoA reductase**. - By inhibiting this enzyme, statins reduce the synthesis of **mevalonate**, a precursor to **cholesterol**, thereby lowering LDL-cholesterol levels. *Gemfibrozil* - **Gemfibrozil** is a **fibrate**, a class of drugs that primarily act by activating **peroxisome proliferator-activated receptor alpha (PPAR-α)**. - Its main effect is to decrease **triglyceride** levels and increase **HDL cholesterol**, not directly inhibit HMG-CoA reductase. *Clofibrate* - **Clofibrate** is also a **fibrate** and operates similarly to gemfibrozil by activating **PPAR-α**. - It primarily reduces **triglycerides** and has a modest effect on increasing HDL, but does not inhibit HMG-CoA reductase. *Nicotinic acid* - **Nicotinic acid** (niacin or vitamin B3) reduces hepatic synthesis of **VLDL** and inhibits the release of **fatty acids** from adipose tissue. - This leads to a decrease in **LDL cholesterol** and triglycerides, and an increase in **HDL cholesterol**, but it does not directly inhibit HMG-CoA reductase.

Q: Fish oil is not used in the treatment of:

Type 2A Hyperlipoproteinemia. ***Type 2A Hyperlipoproteinemia*** - **Fish oil** (omega-3 fatty acids) primarily lowers **triglyceride** levels. - In **Type 2A hyperlipoproteinemia**, the main lipid abnormality is elevated **LDL cholesterol**, with normal triglycerides, making fish oil less effective as a primary treatment. *Type 2B Hyperlipoproteinemia* - This condition involves elevated **LDL cholesterol** and moderately elevated **triglycerides**. - **Fish oil** can be beneficial in managing the elevated triglyceride component. *Type 5 Hyperlipoproteinemia* - Characterized by very high **triglyceride** levels and elevated **chylomicrons** and **VLDL**. - **Fish oil** is a key therapeutic agent for significantly reducing triglycerides in this severe form of hyperlipidemia. *Type 3 Hyperlipoproteinemia* - Also known as **familial dysbetalipoproteinemia**, this condition involves elevated **chylomicron remnants** and **VLDL remnants**. - **Fish oil** can help lower the triglyceride-rich lipoproteins seen in this disorder.

Q: Which drug is primarily known for inhibiting cardiac remodeling in congestive heart failure (CHF)?

ACE inhibitors. ***ACE inhibitors*** - **Angiotensin-converting enzyme (ACE) inhibitors** prevent the conversion of angiotensin I to angiotensin II, reducing detrimental effects like **vasoconstriction**, **aldosterone secretion**, and **cardiac hypertrophy**. - By inhibiting the **renin-angiotensin-aldosterone system (RAAS)**, ACE inhibitors effectively reduce cardiac preload and afterload, leading to the prevention or reversal of **cardiac remodeling**. *Digitalis* - Digitalis primarily acts as a **positive inotrope**, increasing the force of myocardial contraction, and slowing the heart rate, particularly in **atrial fibrillation**. - While it improves symptoms, it does not directly prevent or reverse **cardiac remodeling** and can have a narrow therapeutic index. *Diuretics* - Diuretics primarily reduce **fluid overload** and congestion in CHF by increasing **sodium and water excretion**, thereby decreasing preload. - They alleviate symptoms like **edema** and **dyspnea** but do not directly target or inhibit the underlying processes of **cardiac remodeling**. *Vasodilators* - Vasodilators (such as nitrates and hydralazine) reduce **cardiac preload** and/or **afterload**, improving symptomatic relief. - While they can improve hemodynamics, their primary action is not focused on preventing the cellular and structural changes associated with **cardiac remodeling**.

Q: All of the following are seen in digitalis toxicity except:

Paroxysmal atrial tachycardia with fast ventricular rate. ***Paroxysmal atrial tachycardia with fast ventricular rate*** - Digitalis toxicity typically causes **bradyarrhythmias** or **tachyarrhythmias** with AV block, leading to a slow or normal ventricular rate. - A **fast ventricular rate** in the presence of paroxysmal atrial tachycardia (PAT) suggests that the AV node is conducting impulses unimpeded, which is less likely in digitalis toxicity due to its negative dromotropic effects. *Ventricular bigeminy* - This is a **classic arrhythmia** seen in digitalis toxicity, characterized by alternating normal and premature ventricular beats. - Digitalis increases intracellular calcium and can lead to **delayed afterdepolarizations**, initiating ventricular ectopy. *Regularization of atrial fibrillation* - Digitalis can **slow AV nodal conduction** and increase ventricular refractoriness, which may lead to regularization of the ventricular response in atrial fibrillation. - While not a complete reversal of atrial fibrillation, the **ventricular rhythm becomes more regular** due to increased AV nodal block. *Bidirectional ventricular tachycardia* - This is a highly specific but **rare arrhythmia** associated with severe digitalis toxicity, characterized by alternating QRS complexes in opposite directions. - It results from enhanced automaticity and altered conduction properties in the **His-Purkinje system**.

Q: ACE inhibitors, when used for a long time in hypertensive patients, cause

Reduction in filtration fraction. **Reduction in filtration fraction** - ACE inhibitors cause **vasodilation of the efferent arteriole** in the glomerulus. - This vasodilation leads to a **decrease in glomerular filtration pressure**, thereby reducing the filtration fraction. *Rightward shift in Renal pressure natriuresis curve* - A rightward shift in the renal pressure natriuresis curve indicates that a **higher blood pressure is required to excrete the same amount of sodium and water**. - ACE inhibitors typically cause a **leftward shift of this curve** by improving sodium and water excretion at lower pressures. *Significant increase in heart rate* - ACE inhibitors typically cause a **decrease or no significant change in heart rate**, as they interfere with the renin-angiotensin-aldosterone system (RAAS), which can affect sympathetic tone. - A significant increase in heart rate is **not a common or expected side effect** of long-term ACE inhibitor use. *No change in the compliance of large arteries* - Long-term use of ACE inhibitors can actually **improve arterial compliance** by remodeling the vessel walls and reducing stiffness. - This effect contributes to their **beneficial cardiovascular outcomes** beyond just blood pressure reduction.

Q: Which of the following is a Rho kinase inhibitor?

Fasudil. ***Fasudil*** - **Fasudil** is a well-known and clinically used **Rho kinase inhibitor**, primarily used in Japan for the treatment of **cerebral vasospasm** after subarachnoid hemorrhage. - It works by inhibiting the phosphorylation of **myosin light chain**, leading to **vasodilation**. *Ranolazine* - **Ranolazine** is an anti-anginal drug that works by selectively inhibiting the **late sodium current (I_Na)** in cardiac myocytes. - This reduces intracellular sodium and calcium overload, thereby improving myocardial relaxation and reducing oxygen demand, but it has no direct inhibitory effect on Rho kinase. *Amiloride* - **Amiloride** is a **potassium-sparing diuretic** that directly inhibits the **epithelial sodium channel (ENaC)** in the collecting duct. - It is used to treat **hypertension** and heart failure, preventing potassium loss, and is not associated with Rho kinase inhibition. *Nicorandil* - **Nicorandil** is an anti-anginal drug with a dual mechanism, acting as both a **potassium channel opener** and a **nitrate donor**. - Its vasodilatory effects are mediated through increasing cGMP (like nitrates) and hyperpolarizing vascular smooth muscle cells (like potassium channel openers), but it is not a Rho kinase inhibitor.

Q: The drug of choice for prompt relief of an ongoing attack of angina precipitated by exercise or emotional stress is:

Sublingual nitroglycerin. ***Sublingual nitroglycerin*** - **Sublingual nitroglycerin** acts rapidly (within 1-3 minutes) by causing **vasodilation**, primarily of veins, which reduces **preload** and myocardial oxygen demand, providing prompt relief of anginal symptoms. - It works by releasing **nitric oxide**, leading to **smooth muscle relaxation** in blood vessels, which is critical for acute attack termination. *Propranolol* - **Propranolol** is a **beta-blocker** used for long-term prevention of angina by reducing heart rate and contractility, thereby decreasing oxygen demand. - It is **not suitable for acute relief** as its onset of action is not rapid enough to abort an ongoing anginal attack. *Verapamil* - **Verapamil** is a **calcium channel blocker** that reduces heart rate, contractility, and causes vasodilation, making it useful for angina prevention. - While it can improve oxygen supply, its onset of action is **too slow** for acute symptomatic relief of an ongoing anginal attack. *Sublingual nifedipine* - **Nifedipine** is a **dihydropyridine calcium channel blocker** predominantly used for hypertension and stable angina, primarily causing arterial vasodilation. - Sublingual nifedipine can cause a **rapid and substantial drop in blood pressure**, which can lead to reflex tachycardia and potentially worsen angina or cause adverse cardiovascular events; therefore, it is **not recommended for acute anginal relief**.

Question 1

All of the following are centrally acting antihypertensive drugs except:

Accepted Answer

Trimethoprim

Answer

Methyldopa

Answer

Clonidine

Answer

Guanabenz

Question 2

Most common digoxin-induced arrhythmia is

Accepted Answer

Ventricular Premature Beats

Answer

Ventricular bigeminy

Answer

Atrial Flutter

Answer

Ventricular Fibrillation

Question 3

Effects of beta blockers on the heart are all of the following except:

Accepted Answer

Decreases duration of systole

Answer

Decrease in heart rate

Answer

May decrease cardiac output initially.

Answer

May precipitate heart failure in acute settings.

Question 4

HMG-CoA reductase is inhibited by:

Accepted Answer

Lovastatin

Answer

Gemfibrozil

Answer

Nicotinic acid

Answer

Clofibrate

Question 5

Fish oil is not used in the treatment of:

Accepted Answer

Type 2A Hyperlipoproteinemia

Answer

Type 2B Hyperlipoproteinemia

Answer

Type 5 Hyperlipoproteinemia

Answer

Type 3 Hyperlipoproteinemia

Question 6

Which drug is primarily known for inhibiting cardiac remodeling in congestive heart failure (CHF)?

Accepted Answer

ACE inhibitors

Answer

Digitalis

Answer

Diuretics

Answer

Vasodilators

Question 7

All of the following are seen in digitalis toxicity except:

Accepted Answer

Paroxysmal atrial tachycardia with fast ventricular rate

Answer

Ventricular bigeminy

Answer

Regularization of atrial fibrillation

Answer

Bidirectional ventricular tachycardia

Question 8

ACE inhibitors, when used for a long time in hypertensive patients, cause

Accepted Answer

Reduction in filtration fraction

Answer

Rightward shift in Renal pressure natriuresis curve

Answer

Significant increase in heart rate

Answer

No change in the compliance of large arteries

Question 9

Which of the following is a Rho kinase inhibitor?

Accepted Answer

Fasudil

Answer

Ranolazine

Answer

Amiloride

Answer

Nicorandil

Question 10

The drug of choice for prompt relief of an ongoing attack of angina precipitated by exercise or emotional stress is:

Accepted Answer

Sublingual nitroglycerin

Answer

Propranolol

Answer

Verapamil

Answer

Sublingual nifedipine

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?